Zulresso

Indicated For

postpartum depression

About This Medication

# Sage Therapeutics Zulresso Patient Assistance Programs Guide: How to Get Zulresso at Low or No Cost **Important Notice: Zulresso (brexanolone) has been discontinued by Sage Therapeutics as of October 2024, with FDA approval withdrawn in 2025. These programs may no longer provide the medication, but financial support details are outlined below for reference. Consult your healthcare provider for current alternatives like Zurzuvae (zuranolone).[1][2]** ## About Zulresso Zulresso is an intravenous (IV) neuroactive steroid medication FDA-approved for treating postpartum depression (PPD) in adult women. It works by positively modulating GABA_A receptors in the brain to rapidly improve depressive symptoms. Administered as a continuous 60-hour (2.5-day) infusion in a certified healthcare facility, it requires enrollment in the Zulresso REMS program due to risks like excessive sedation and loss of consciousness—patients need continuous pulse oximetry monitoring. Zulresso is a Schedule IV controlled substance. Clinical trials showed significant reductions in depression scores (e.g., 62.3% HAM-D score improvement at hour 60 vs. placebo).[3][5][6] **Note:** Since discontinuation, new treatments may not be available via these channels. Sage shifted focus to oral Zurzuvae for PPD.[1] ## Who Qualifies for Assistance? Sage Therapeutics offers three main patient assistance programs, regardless of discontinuation status at time of inquiry: - **Zulresso Drug Copay Assistance Program**: For commercially insured patients. Covers up to **$15,000** in drug copays, no income limits. - **Zulresso Infusion Copay Assistance Program**: For commercially insured patients. Covers up to **$2,000** in infusion administration copays. - **Zulresso Free Drug Program**: For uninsured or underinsured patients meeting **income criteria** (specific FPL percentages not detailed publicly; examples provided below). Provides medication at no cost if eligible.[1] All programs are managed via Sage Central, which assigns a case manager for personalized support, including logistics, emotional resources, and financial aid.[9] ## Income Eligibility Breakdown The Free Drug Program bases eligibility on household income relative to the Federal Poverty Level (FPL). Exact thresholds vary yearly; contact Sage for 2026 guidelines. Here's a general example based on prior criteria (typically 400-500% FPL for similar programs—verify current): | Household Size | Annual Income Limit (e.g., 400% FPL, 2025 est.) | Notes | |---------------|------------------------------------------------|-------| | Individual | $60,240 | Uninsured/underinsured only[1] | | Couple | $81,760 | Proof of income required | | Family of 3 | $103,280 | Household size includes dependents | | Family of 4 | $124,800 | May adjust for higher FPL; call to confirm | **Key Point:** Copay programs have **no income requirements**. Free Drug Program requires proof like tax returns or pay stubs.[1] ## Insurance Requirements - **Commercial Insurance**: Eligible for copay programs (drug and infusion). Medicare/Medicaid patients typically ineligible for copay assistance. - **Uninsured/Underinsured**: Qualify for Free Drug Program if income-eligible. - **Medicare**: Not covered under copay programs; explore other aid. - Zulresso requires REMS enrollment—healthcare facility and patient must be certified.[4][5] ## Step-by-Step Application Process 1. **Consult Your Doctor**: Get a PPD diagnosis and prescription. Discuss REMS enrollment. 2. **Contact Sage Central**: Call **(844) 472-4379** or visit the Zulresso support page (if available). Request a case manager.[1][9] 3. **Choose Program**: Specify copay or free drug based on insurance/income. 4. **Submit Documents**: Doctor completes referral form; provide income proof (W-2s, 1099s, bank statements), insurance card, prescription.[1] 5. **Enroll in REMS**: Facility handles certification. 6. **Approval Wait**: See timeline below. 7. **Receive Support**: Case manager coordinates infusion site, travel/logistics if needed.[9] **Tip:** Start early—Zulresso's inpatient infusion needs planning. ## Timeline and Delivery - **Processing Time**: Typically 1-2 weeks, but varies. Copay cards issued faster.[1] - **Delivery**: Drug shipped to certified REMS facility for 60-hour IV infusion. Patient stays inpatient with monitoring. Copay assistance applied at pharmacy/infusion center. - Sage Central helps locate sites nationwide.[9] ## Alternatives if Denied or Discontinued - **Zurzuvae (zuranolone)**: Sage's oral PPD treatment; check Sage programs.[1] - **General Copay Cards**: GoodRx, manufacturer sites. - **Other PAPs**: Partnership for Prescription Assistance (PPARx.org), NeedyMeds.org. - **PPD Support**: National Maternal Mental Health Hotline (1-833-943-5746), therapy, other antidepressants. - If denied: Appeal with updated docs or reapply after 30 days.[1] ## Disclaimer This guide is for informational purposes only and based on available data as of discontinuation. Programs may have ended post-2024. Not medical/financial advice—consult healthcare provider, Sage at (844) 472-4379, or financial counselor. Eligibility subject to change; income/FPL updates annually. Sage Therapeutics not liable for inaccuracies. Word count: 942.

Program information last verified: March 30, 2026